Search

Displaying results 4861 - 4870 of 10000 in total
  1. Drug

    GW 468816

    go.drugbank.com/drugs/DB05417
    Investigational

    GW 468816 is glycine receptor antagonist. It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.

    Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitors
  2. Drug

    BCc1

    go.drugbank.com/drugs/DB16504
    Experimental

    BCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.

  3. Drug

    Quinacrine

    go.drugbank.com/drugs/DB01103
    Investigational

    It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2. … An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years.

  4. Drug

    PR-104

    go.drugbank.com/drugs/DB05968
    Investigational

  5. Drug

    CPD 923

    go.drugbank.com/drugs/DB05856
    Experimental

    CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.

  6. Drug

    Mocetinostat

    go.drugbank.com/drugs/DB11830
    Investigational

    Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.

  7. Drug

    AZD-6482

    go.drugbank.com/drugs/DB14980
    Investigational

    AZD-6482 is under investigation in clinical trial NCT00688714 (Study to Investigate Safety and Tolerability of a Single Dose of AZD6482).

    Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors
  8. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).

  9. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    Blonanserin is an atypical antipsychotic approved in Japan in January, 2008. … As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics.

  10. Drug

    Isoxsuprine

    go.drugbank.com/drugs/DB08941
    ApprovedWithdrawn

    Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.